Ionis Pharmaceuticals Drops Another After Phase 3 Setback
Ionis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
Curious about which travel cards have no annual fees? Find the best options to maximize your travel rewards.
26,862 articlesIonis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
A fresh BIT report shows the long-standing links between stocks, gold, and Bitcoin breaking down as investors chase s...
A top tech analyst argues memory chips are the AI backbone, with a widening 15-to-1 demand-to-supply gap shaping mark...
Tuesday brought a modest pullback for Salesforce as tech stocks wobbled. This article explains the drivers behind the...
Chinese memory-maker CXMT gears up for a high-profile $8.6 billion IPO, sparking renewed pressure on U.S. and Asian m...
Federal investigators say the driver pressed the accelerator to the floor, steering away from the car's auto-drive sy...
Markets recalibrate after a run by the Magnificent Seven, pushing many to rethink concentration. Three ETFs—RSP, SCHV...
When Netflix just reported earnings, the market focused on growth signals, margins, and the path to free cash flow. T...
A high-stakes debate is unfolding around SpaceX and its heavy short interest. This article breaks down what it means ...
Is Nvidia stock going $300? This guide breaks down the odds, the main drivers, and a practical plan for investing in ...
From a brutal 1995 fundraising sprint to a $2+ trillion market cap today, Amazon's origin story centers on relentless...
Seven Hills SEVN 2025 Q4 earnings reveal growth signals, margin dynamics, and a clear plan for 2026. This deep dive b...